“Venciendo Resistencias Adquiridas”
GETNE1509:
TALENT
Primary endpoint:
Response rate by central radiology review (RECIST 1.1)
Main secondary endpoints:
Safety, PFS, early tumor shrinkage, deepness of response, biomarkers
A prospective, multi-center, international, open label, stratified, exploratory phase II study evaluating the
efficacy and safety of lenvatinib in advanced neuroendocrine tumors
•
pNETs after progression to a
previous targeted agent
•
Small intestine NETs after
progression to SSAs
•
G1/G2
N= 110
Cohort A PANCREATIC
Lenvatinib 24 mg qd
Cohort B GASTROINTESTINAL
Lenvatinib 24 mg qd
R
